Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling-Reference-Cited by-同舟云学术

Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling

Published:2013-01-04 Issue:2 Volume:31 Page:151-161
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Asukai Yumi,Baldwin Michael,Fonseca Tiago,Gray Alastair,Mungapen Laura,Price David

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-012-0016-3/fulltext.html

Reference37 articles.

1. World Health Organization. Chronic obstructive pulmonary disease (COPD): fact sheet no. 315. Geneva: WHO: 2011.

2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. Bethesda: GOLD; 2011.

3. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(2 Suppl):5S–9S.

4. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: NICE; 2010.

5. Rutten-van Molken MP, Goossens L. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30(4):271–302.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model;Applied Health Economics and Health Policy;2022-04-28

2. Multidisciplinary efforts in combating nonadherence to medication and health care interventions: Opportunities and challenges for operations researchers;IISE T HEALTHC SYST;2021

3. Patient pathway modelling using discrete event simulation to improve the management of COPD;Journal of the Operational Research Society;2020-12-30

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

;International Journal of Chronic Obstructive Pulmonary Disease;2020-04

5. Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada;Medical Decision Making;2019-01-24